Regulations

Two years after legalizing, Vermont lawmakers have reached a final agreement on their proposal for a regulated adult-use cannabis marketplace.

A new study from the Yale School of Public Health shows that states with legal cannabis access experienced fewer cases of the vaping lung disease EVALI.

New emergency rules in Florida allow for the manufacturing and sale of medical cannabis-infused edibles. The rules take effect immediately.

Hempcrete has been used for decades as a sustainable option in construction materials — in the U.S., however, many hempcrete pioneers are stuck navigating outdated building codes and other local regulations.

Following a spate of EVALI cases in 2019, the vaping-related lung disease has received little attention in the months since COVID-19. One year later, we’re left wondering: what happened, how did it happen, and what could have been done differently?

Michigan regulators ordered the recall of about 3,200 pre-rolls after an employee allegedly licked one of the pre-rolls while making the product.

Massachusetts regulators have eased restrictions on more than 600,000 cannabis vape products that were quarantined last November amid a national trend of vape-related lung injuries.

Massachusetts Cannabis Control Commissioner Shaleen Title says she is starting to feel “embarrassed” by inequities in the state’s cannabis industry.

CW Nevada has received a $1.25 million fine from the Nevada Cannabis Compliance Board following multiple alleged violations, including selling untested and unregistered cannabis products.

A proposal from the California Assembly would levy civil fines up to $30,000 per day to anyone who provides building space, advertising platforms, and other services to unlicensed cannabis operators.

The USDA has officially approved Minnesota’s hemp cultivation program; the final regulations are unchanged from the state’s 2016 pilot program.

Jamaican officials have unveiled new medical cannabis control standards that are aimed at positioning local businesses for success in the global cannabis market.

Massachusetts regulators have issued $800k in fines to three companies for improper pesticide use and other regulatory infractions.

Medical cannabis firm Ultra Health is asking a district court judge to invalidate new cannabis testing, labeling, and facility safety rules in New Mexico, calling them “arbitrary and capricious.”

A Grand Jury report has condemned cannabis regulations set by the Santa Barbara County Board of Supervisors for mismanaging the local industry and ignoring its environmental impacts.

The Los Angeles city council has unanimously approved new regulations that will tighten up the cannabis social equity program and create rules for licensing new dispensaries in city neighborhoods that have already reached their cap.

San Diego is the latest California city to establish a city-specific agency dedicated to licensing and regulating businesses in the cannabis space.

While there are more U.S. farmers this year who are licensed to grow hemp, total hemp acreage is down 9% from 2019.

Louisiana Gov. Edwards signed legislation this week that regulates hemp and CBD products, including a ban on selling hemp products “for inhalation” except for hemp-based rolling papers.

Ohio’s State Medical Board last week added cachexia, or wasting syndrome, to its qualifying conditions list for medical cannabis. Regulators, however, rejected anxiety and autism spectrum disorder.

Health Canada says the cannabis industry has a generally high rate of compliance, having ordered just 15 product recalls — all due to mislabeled CBD and THC content — since legalizing in 2018.

Iowa’s Senate has approved expansions to the state’s medical cannabis program; the bill is now headed to the governor’s desk, where it is expected to be signed into law.

Washington cannabis regulators have adopted emergency rules banning vitamin E acetate in cannabis vapor products and aim to expand cannabis testing requirements.

Florida’s medical cannabis marketplace is based on the vertical integration of participating companies; this can be good for regulators and tax dollars, but very bad for patients and consumers.